ClinicalTrials.gg
CompletedNCT06950645Updated Mar 20, 2026

The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

A Phase 1 interventional study of Oral hexavalent reassortant rotavirus attenuated live vaccine and Oral hexavalent reassortant rotavirus attenuated live vaccine in Rotavirus Gastroenteritis, sponsored by Sinovac Life Sciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 6 Weeks to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Sinovac Life Sciences Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
6 Weeks to 59 Years
Sex
All
01

Study summary

The Phase I clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in a population ranging from 6 weeks to 59 years of age.

The objective of this study is to evaluate the safety of investigational vaccine in healthy adults and children, as well as its safety tolerability, and immunogenicity in healthy infants.

The study will be an open-label observation in adults and children, and a randomized, double-blind, placebo-controlled clinical trial in infants.

Read the detailed description

The Phase I clinical trial is an open-label observation involving healthy adults and children, as well as a randomized, double-blind, placebo-controlled study in healthy infants to evaluate the safety, tolerability, and immunogenicity of the investigaional vaccine. The investigational vaccine is available in both high-dose and low-dose formulations. The placebo is identical to the trial vaccine in all components except for the rotavirus.

This study will enroll 100 participants, consisting of 20 adults aged 18-59 years, 20 children aged 2-6 years, and 60 infants aged 6-12 weeks. Participants will be enrolled sequentially, starting with adults, followed by children, and then infants. Enrollment for the subsequent group will begin after a 14-day safety observation period and confirmation of acceptable safety in the preceding group. Adult and child participants will receive the investigational vaccine in an open-label manner. The infants will be enrolled into two cohorts of 30 participants each: a low-dose cohort and a high-dose cohort. Within each cohort, the infants will be randomly assigned to two groups at a ratio of 2:1 and will receive either the investigational vaccine or a placebo in a double-blind manner. The immunization schedule for both the vaccine and placebo consists of three doses administered at 28-day intervals.

Adverse events (AE) will be collected for all participants until 42 days after the last dose vaccination. Stool samples will be collected after each vaccination to detect vaccine strain shedding among infant participants. Serious adverse events (SAE) will be observed for 6 months from the last dose for adults and children or 12 months for infants. Blood samples from the infants will be collected at predetermined times to evaluate the immunogenicity of the investigational vaccine.

02

Conditions studied

  • Rotavirus Gastroenteritis

Browse trials for

Keywords

  • Phase I
  • sequential design
  • safety
  • tolerability
  • immunogenicity
  • Rotavirus gastroenteritis
  • vaccine
03

In context

Gastroenteritis

237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.

This study's enrollment of 100 is below the median of 136 across 164 interventional studies indexed under Gastroenteritis.

Browse Gastroenteritis studies →

Lead sponsor

Sinovac Life Sciences Co., Ltd. is the lead sponsor of 26 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant and/or their guardian is willing and able to comply with all study procedures, sign the form, and remain contactable throughout the study period.
  2. Provide legal identification.
  3. Male or female, aged 6 to 12 weeks, or 2 to 6 years, or 18 to 59 years, and in good health.
  4. Fertile participants have no plans for pregnancy from the time of signing the informed consent form until 3 months after the last dose of the study vaccine and agree to use effective , and have no plans for sperm or egg donation.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the vaccine or its components, such as urticaria, dyspnea, angioedema, etc.
  2. Current diarrhea or vomiting, or other gastrointestinal diseases, or having experienced gastroenteritis or any acute illness or acute exacerbation of chronic disease within the past 7 days, or those currently using antibiotics or antiviral therapy.
  3. History of intussusception or chronic gastrointestinal disease, including gastrointestinal congenital anomalies that can easily cause intussusception (e.g., Meckel's diverticulum).
  4. For infant and pediatric participants: congenital malformations or developmental disabilities, genetic defect diseases, severe malnutrition, or severe chronic diseases (such as Down syndrome, diabetes, sickle cell anemia, neurological disorders, Guillain-Barré syndrome); For adult participants: uncontrolled chronic diseases or severe disease history, including but not limited to cardiovascular diseases (such as drug-uncontrolled hypertension, i.e., systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), hematologic diseases, hepatic and renal diseases, gastrointestinal diseases, respiratory diseases, malignant tumors, history of major organ transplantation, or any other disease or medical condition that the investigator believes may interfere with the trial results.
  5. Presence of diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, infection).
  6. Household members living with the participant are in an immunodeficient or state or are currently/soon to be receiving immunosuppressive therapy, cytotoxic therapy, etc.
  7. Presence of coagulation dysfunction (such as deficiency of coagulation factors, abnormal ).
  8. Received >14 days of immunosuppressive therapy or other immunomodulatory therapy, cytotoxic therapy within the past 6 months (for adult and pediatric participants) or since birth (for infant participants), or planned to receive such treatment during the study period.
  9. Chronic alcoholism [weekly alcohol consumption >14 drinking units (1 drinking unit = 14 grams of 100% alcohol = 360 mL beer, or 150 mL wine, or 45 mL distilled spirits/liquor)] or history of drug abuse (repeated, excessive use of narcotic drugs, psychotropic substances, volatile organic solvents, etc.) (for adult participants).
  10. Suffering from/having suffered from severe neurological diseases (epilepsy, convulsions or seizures) or mental illness, or having a family history of the same.
  11. Received immunoglobulin or other blood products within 6 months before receiving the trial vaccine (for adult and pediatric groups) or in the past (for infant group), or planned to receive such treatment during the study period.
  12. Received other drugs or vaccines within the past 30 days, or planned to receive such drugs or vaccines during the study period.
  13. Received or COVID-19 vaccines within the past 14 days, or subunit or inactivated vaccines and other process vaccines within the past 7 days.
  14. Had axillary temperature ≥38.0℃ within the past 3 days.
  15. On the day planned for vaccination with the trial vaccine, having a fever with axillary temperature >37.0℃.
  16. Clinical laboratory tests showing laboratory abnormalities beyond the reference range that are (for adult and pediatric groups):

    • Hematology test indicators: white blood cell count, , platelet count.
    • Biochemical blood test indicators: (ALT), aspartate aminotransferase (AST), total (TBIL), creatinine (CR), fasting blood glucose (Glu).
    • Urinalysis test indicators: urine protein (PRO).
  17. Fertile women with positive urine pregnancy test or breastfeeding.
  18. Currently or planning to participate in other vaccine or drug clinical trials.
  19. Any other factors that the investigator deems unsuitable for participation in the clinical trial.

Additional Exclusion Criteria for Infants Aged 6 to 12 Weeks

  1. Previously received rotavirus vaccine.
  2. History of rotavirus infection.
  3. Neonatal gestational age \<37 weeks or ≥42 weeks.
  4. Birth weight \<2500g.
  5. History of difficult labor, resuscitation from asphyxia, or neurological damage at birth.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Adult

    The experimental vaccine will be administered in three doses, with a 28-day interval between each dose.

    Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine

  • Experimental
    Children

    The experimental vaccine will be administered in three doses, with a 28-day interval between each dose

    Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine

  • Experimental
    Infants low-dose 1

    They will receive three low-dose experimental vaccine in a double-blind setting, with a 28-day interval between each dose.

    Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine

  • Placebo comparator
    Infants low-dose 2

    They will receive three doses of the placebo in a double-blind setting, with a 28-day interval between each dose

    Biological: Placebo

  • Experimental
    Infants high-dose 1

    They will receive three high-dose experimental vaccine in a double-blind setting, with a 28-day interval between each dose

    Biological: Oral hexavalent reassortant rotavirus attenuated live vaccine

  • Placebo comparator
    Infants high-dose 2

    They will receive three doses of the placebo in a double-blind setting,with a 28-day interval between each dose

    Biological: Placebo

Interventions

  • BiologicalOral hexavalent reassortant rotavirus attenuated live vaccine

    Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

  • BiologicalOral hexavalent reassortant rotavirus attenuated live vaccine

    Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

  • BiologicalOral hexavalent reassortant rotavirus attenuated live vaccine

    Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally

  • BiologicalPlacebo

    Placebo of experimental vaccine for infants three doses administered orally

  • BiologicalOral hexavalent reassortant rotavirus attenuated live vaccine

    Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

  • BiologicalPlacebo

    Placebo of experimental vaccine for infants three doses administered orally

06

What researchers measure

Primary outcomes

  1. Evaluate the safety of the investigational vaccine

    Incidence of adverse events/reactions

    Time frame: 0 day after the first dose till 42 days after the last dose

Secondary outcomes

  1. Evaluate the safety of the investigational vaccine

    Incidence of adverse events/reactions

    Time frame: 0-14 days after each dose

  2. Evaluate the safety of the investigational vaccine

    Incidence of adverse events/reactions

    Time frame: 0-30 minutes after each dose

  3. Evaluate the safety of the investigational vaccine in the healthy adults and children groups

    Incidence of clinically significant abnormal laboratory parameters on day 3 after each dose in adult and children groups

    Time frame: day 3 after each dose

  4. Evaluate the safety of the investigational vaccine

    Incidence of serious adverse events (SAEs)

    Time frame: Within 6 months after the last dose

  5. Evaluate the safety of the investigational vaccine in the healthy infant group

    Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs)

    Time frame: Within 12 months after the last dose in the infant group

  6. Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.

    Seroconversion rate of serum IgA antibodies against vaccine serotype rotavirus.

    Time frame: 28 days after the full vaccination course

  7. Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.

    Seropositivity rate of serum IgA antibodies against vaccine serotype rotavirus.

    Time frame: 28 days after the full vaccination course

  8. Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.

    Geometric mean concentration (GMC) of serum IgA antibodies against vaccine serotype rotavirus.

    Time frame: 28 days after the full vaccination course

  9. Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.

    Geometric mean increase (GMI) of serum IgA antibodies against vaccine serotype rotavirus.

    Time frame: 28 days after the full vaccination course

  10. Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.

    Seropositivity rate of serum IgA antibodies against vaccine serotype rotavirus

    Time frame: 6 months and 12 months after the full vaccination course

  11. Evaluate the immunogenicity and immune persistence of the investigated vaccine in healthy infants.

    Geometric mean concentration (GMC) of serum IgA antibodies against vaccine serotype rotavirus

    Time frame: 6 months and 12 months after the full vaccination course

  12. Evaluate the fecal shedding of investigated vaccine strain in healthy infants after vaccination.

    The shedding rate of the rotavirus vaccine strain in the stool.

    Time frame: 0-14 days after each dose

  13. Evaluate the fecal shedding of investigated vaccine strain in healthy infants after vaccination.

    The shedding duration of the rotavirus vaccine strain in the stool.

    Time frame: 0-14 days after each dose

  14. Evaluate the reassortment and reversion of the rotavirus vaccine strain in stool samples of healthy infants after vaccination

    The incidence of reassortment and reversion of the rotavirus vaccine strain in stool samples.

    Time frame: 0-14 days after each dose,

07

Study locations

1 site
  • Hebei Provincial Center for Disease Control and Prevention
    Shijiazhuang, Hebei 050021, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Dec 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
Apr 30, 2025
StartActual
Mar 27, 2024
Primary completionActual
Dec 21, 2024
CompletionActual
Dec 18, 2025
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06950645
Responsible party
Sponsor
First posted
Apr 30, 2025
Start date
Mar 27, 2024
Primary completion
Dec 21, 2024
Completion
Dec 18, 2025
Last update
Mar 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion